Zura Bio Limited SEC Filings

Zura Bio Limited furnished a press release announcing its third quarter 2025 financial results. The release was provided as Exhibit 99.1 to a Form 8-K dated November 13, 2025. Under Item 2.02, the information (including Exhibit 99.1) is deemed furnished, not filed, and is not incorporated by reference except as specifically stated.

Zura Bio Limited ownership disclosure: A group led by Venrock entities and two individuals reports beneficial ownership of 6,353,353 Class A Ordinary Shares, representing 9.99% of the class as of June 30, 2025. The position reflects direct Class A shares and pre-funded warrants exercisable into additional Class A shares, but those warrants include a Beneficial Ownership Blocker that prevents exercise that would push the group above the 9.99% threshold. The percentage is calculated using 61,874,998 outstanding Class A shares plus 1,722,137 shares issuable on warrant exercise. Voting and dispositive power are shown as shared for the 6,353,353 shares, with no sole voting or dispositive power reported.

Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report a collective stake of 4,616,514 Class A Ordinary Shares in ZURA Bio Ltd, representing 7.13% of the class. The filing shows the reporting persons hold shared voting and shared dispositive power for all 4,616,514 shares and no sole voting or dispositive power. The ownership calculation uses a share base of 64,763,950, which combines 61,874,998 outstanding ordinary shares and 2,882,952 pre-funded warrants that the reporting persons could convert subject to a 9.99% maximum exercise limitation. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.

Zura Bio Limited reported advancing clinical programs while continuing to operate at a loss. As of June 30, 2025 the company held $154.5 million in cash and cash equivalents and reported a net loss of $15.993 million for the three months ended June 30, 2025 and $33.435 million for the six months ended June 30, 2025, leaving an accumulated deficit of $189.3 million. The balance sheet shows total assets of $157.8 million and total shareholders' equity of $127.4 million.

The company is a clinical-stage immunology company developing tibulizumab (ZB-106), which entered a global Phase 2 study TibuSHIELD in May 2025 (~180 adults) and previously initiated TibuSURE (Dec 2024, ~80 participants). Zura also lists two other clinical assets, crebankitug and torudokimab. The filing discloses contingent milestone and royalty obligations under multiple license agreements and a pending $5.0 million invoice related to a finder’s fee that the company is reviewing. Management states it expects existing liquidity to fund operations for the next twelve months.

Zura Bio Limited furnished a press release announcing its second quarter 2025 financial results and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states the results disclosure is furnished under Item 2.02 rather than "filed," and the press release itself is incorporated by reference into the exhibit list.

The company also confirms its securities trading symbol and that it qualifies as an emerging growth company. No financial tables, specific revenue, earnings or other numeric results are included within the 8-K text; interested readers must refer to Exhibit 99.1 for the full press release content.